Revenue Recognition

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenue Recognition

(9)      Revenue Recognition

Revenue from Product Sales

The following tables present the Company’s revenue disaggregated by business segment and geography, based on management’s assessment of available data:

	Three Months Ended June 30, 2022							Three Months Ended June 30, 2021
	U.S.		Outside U.S.		Total Revenues		% of Total Revenues	U.S.		Outside U.S.		Total Revenues		% of Total Revenues
Radiochemical Products	$	1,266,249	$	113,790	$	1,380,039	57%	$	1,091,114	$	137,095	$	1,228,209	45%
Cobalt Products		89,946		9,200		99,146	4%		562,744		14,250		576,994	21%
Nuclear Medicine Products		744,154		211,469		955,623	39%		768,349		186,344		954,693	34%
Fluorine Products		—		—		—	0%		—		—		—	0%
	$	2,100,349	$	334,459	$	2,434,808	100%	$	2,422,207	$	337,689	$	2,759,896	100%

	Six Months Ended June 30, 2022							Six Months Ended June 30, 2021
	U.S.		Outside U.S.		Total Revenues		% of Total Revenues	U.S.		Outside U.S.		Total Revenues		% of Total Revenues
Radiochemical Products	$	2,776,571	$	229,391	$	3,005,962	57%	$	1,637,924	$	251,462	$	1,889,386	40%
Cobalt Products		256,502		14,550		271,052	5%		676,023		19,344		695,367	15%
Nuclear Medicine Products		1,584,536		380,699		1,965,235	38%		1,712,205		433,437		2,145,642	45%
Fluorine Products		—		—		—	0%		22,013		—		22,013	0%
	$	4,617,609	$	624,640	$	5,242,249	100%	$	4,048,165	$	704,243	$	4,752,408	100%

The Company’s revenue consists primarily of calibration and reference standards manufactured for use in the nuclear medicine industry, distribution of radiochemicals including sodium iodide I-131 drug product, and cobalt source manufacturing. With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products is considered to be two to three years. Accordingly, preliminary payments received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue on the Company’s condensed consolidated balance sheets and classified under current or long-term liabilities, depending upon estimated ship dates. For the six months ended June 30, 2022, the Company reported current unearned revenue of $1,050,084. For the period ended December 31, 2021, the Company reported current unearned revenue of $907,953. These unearned revenues will be recognized as revenue in the periods during which the cobalt shipments take place.

Accounts Receivable

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied.  As of June 30, 2022, and December 31, 2021, accounts receivable totaled $1,301,822 and $853,675, respectively.  For the six months ended June 30, 2022, the Company has an allowance for doubtful accounts of approximately $19,000.